Safety study of fedratinib in Korean patients with myelofibrosis
Part of Blood & lymphatic clinical trials.
This study looks at the safety of the drug fedratinib in Korean patients with myelofibrosis. It will help doctors better understand how well patients tolerate the drug when it's used as approved.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years of age or older
- You have been prescribed fedratinib by your doctor for a use that is approved in Korea
- You are willing to sign a consent form agreeing to take part
- Your use of fedratinib must follow the approved instructions (dose and indication) as per Korean health authorities
- You must not have any medical condition that makes taking fedratinib unsafe for you, as per the approved prescribing information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
This program provides continued access to the study drug fedratinib for people who previously received it in a clinical trial before January 31, 2018. It ensures you can keep taking the medication if you benefited from it and no other trial is available.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.